Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Metastasis | Research article

Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis

Authors: Jiefeng Zhao, Jinfeng Zhu, Rui Sun, Chao Huang, Rongfa Yuan, Zhengming Zhu

Published in: BMC Cancer | Issue 1/2021

Abstract

Purpose

Studies on unresectable colorectal cancer liver metastasis(CRLM) rarely analyze the prognosis of the patients from the point of colonic subsites. We aimed to evaluate the effect of primary tumor resection (PTR) and different scope of colectomy on the prognosis of patients with unresectable transverse colon cancer liver metastasis (UTCLM), hepatic flexure cancer liver metastasis (UHFLM), and splenic flexure cancer liver metastasis (USFLM).

Patients and methods

The patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Cox proportional hazards regression models were used to identify prognostic factors of overall survival (OS) and cause-specific survival (CSS). Kaplan-Meier analyses and log-rank tests were conducted to assess the effectiveness of PTR on survival.

Results

In total, this study included a cohort of 1960 patients: 556 cases of UHFLM, 1008 cases of UTCLM, and 396 cases of USFLM. The median survival time of whole patients was 11.0 months, ranging from 7.0 months for UHFLM patients to 15.0 months for USFLM patients. USFLM patients had the best OS and CSS, followed by UTCLM patients. UHFLM patients had the worst OS and CSS (All P < 0.001). PTR could improve the OS and CSS of UTCLM, UHFLM, and USFLM (All P < 0.001). Subgroups analysis revealed that USFLM patients with tumor size≤5 cm and negative CEA had not demonstrated an improved OS and CSS after PTR. Multivariate analysis showed that PTR and perioperative chemotherapy were common independent prognostic factors for UHFLM, UTCLM, and USFLM patients. There was no difference between segmental colon resection and larger colon resection on CSS of UHFLM, UTCLM, and USFLM patients.

Conclusions

We confirmed the different survival of patients with UTCLM, UHFLM, and USFLM, and for the first time, we proved that PTR could provide survival benefits for patients with unresectable CRLM from the perspective of colonic subsites of transverse colon, hepatic flexure, and splenic flexure. Besides, PTR may not improve the prognosis of USFLM patients with CEA- negative or tumor size≤5 cm. For oncologic outcomes, we concluded that segmental colon resection seemed an effective surgical procedure for UTCLM, UHFLM, and USFLM.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.CrossRef

Ottaiano A, Caraglia M, Di Mauro A, Botti G, Lombardi A, Galon J, et al. Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers (Basel). 2020;12(10):3073. https://doi.org/10.3390/cancers12103073.

Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23(9):2038–48. https://doi.org/10.1200/JCO.2005.00.349.CrossRefPubMed

Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74. https://doi.org/10.1002/bjs.5278.CrossRefPubMed

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9. https://doi.org/10.1097/01.sla.0000217629.94941.cf.CrossRefPubMedPubMedCentral

Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol. 2014;21(2):501–6. https://doi.org/10.1245/s10434-013-3297-7.CrossRefPubMed

Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–35. https://doi.org/10.1097/SLA.0b013e31815aa2c2.CrossRefPubMed

Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25; discussion 825-817. https://doi.org/10.1097/01.sla.0000128305.90650.71.CrossRefPubMedPubMedCentral

Lillemoe HA, Vauthey JN. Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy. Hepatobiliary Surg Nutr. 2020;9(1):25–34. https://doi.org/10.21037/hbsn.2019.05.14.CrossRefPubMedPubMedCentral

10.

Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231(5):743–51. https://doi.org/10.1097/00000658-200005000-00015.CrossRefPubMedPubMedCentral

11.

Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I.CrossRefPubMed

12.

de Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol. 2014;6(6):156–69. https://doi.org/10.4251/wjgo.v6.i6.156.CrossRefPubMedPubMedCentral

13.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: Colon Cancer, version 2.2018. J Natl Compr Cancer Netw. 2018;16(4):359–69. https://doi.org/10.6004/jnccn.2018.0021.CrossRef

14.

Li CL, Tang DR, Ji J, Zang B, Chen C, Zhao JQ. Colorectal adenocarcinoma patients with M1a diseases gain more clinical benefits from palliative primary tumor resection than those with M1b diseases: a propensity score matching analysis. World J Clin Cases. 2020;8(15):3230–9. https://doi.org/10.12998/wjcc.v8.i15.3230.CrossRefPubMedPubMedCentral

15.

Tarantino I, Warschkow R, Worni M, Cerny T, Ulrich A, Schmied BM, et al. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal Cancer patients: a population-based, Propensity Score-Adjusted Trend Analysis. Ann Surg. 2015;262(1):112–20. https://doi.org/10.1097/SLA.0000000000000860.CrossRefPubMed

16.

Gulack BC, Nussbaum DP, Keenan JE, Ganapathi AM, Sun Z, Worni M, et al. Surgical resection of the primary tumor in stage IV colorectal Cancer without Metastasectomy is associated with improved overall survival compared with chemotherapy/radiation therapy alone. Dis Colon Rectum. 2016;59(4):299–305. https://doi.org/10.1097/DCR.0000000000000546.CrossRefPubMedPubMedCentral

17.

Xu J, Ma T, Ye Y, Pan Z, Lu D, Pan F, et al. Surgery on primary tumor shows survival benefit in selected stage IV colon cancer patients: a real-world study based on SEER database. J Cancer. 2020;11(12):3567–79. https://doi.org/10.7150/jca.43518.CrossRefPubMedPubMedCentral

18.

Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomark Prev. 2003;12(8):755–62.

19.

Ghazi S, Lindforss U, Lindberg G, Berg E, Lindblom A, Papadogiannakis N. Low-risk colorectal Cancer study G. analysis of colorectal cancer morphology in relation to sex, age, location, and family history. J Gastroenterol. 2012;47(6):619–34. https://doi.org/10.1007/s00535-011-0520-9.CrossRefPubMed

20.

Xi Y, Yuefen P, Wei W, Quan Q, Jing Z, Jiamin X, et al. Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer. J Transl Med. 2019;17(1):353. https://doi.org/10.1186/s12967-019-2102-1.CrossRefPubMedPubMedCentral

21.

Shapiro M, Rashid NU, Whang EE, Boosalis VA, Huang Q, Yoon C, et al. Trends and predictors of resection of the primary tumor for patients with stage IV colorectal cancer. J Surg Oncol. 2015;111(7):911–6. https://doi.org/10.1002/jso.23906.CrossRefPubMed

22.

Yang Y, Lu Y, Jiang W, Zhu J, Yan S. Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer. World J Surg Oncol. 2020;18(1):193. https://doi.org/10.1186/s12957-020-01972-y.CrossRefPubMedPubMedCentral

23.

Ergun Y, Bal O, Dogan M, Ucar G, Dirikoc M, Acikgoz Y, et al. Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer? J Res Med Sci. 2020;25(1):14. https://doi.org/10.4103/jrms.JRMS_1056_18.CrossRefPubMedPubMedCentral

24.

Tharin Z, Blanc J, Alaoui IC, Bertaut A, Ghiringhelli F. Influence of primary tumor location and resection on survival in metastatic colorectal cancer. World J Gastrointest Oncol. 2020;12(11):1296–310. https://doi.org/10.4251/wjgo.v12.i11.1296.CrossRefPubMedPubMedCentral

25.

Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, et al. Association between primary tumor location and prognostic survival in synchronous colorectal liver metastases after surgical treatment: a retrospective analysis of SEER data. J Cancer. 2019;10(7):1593–600. https://doi.org/10.7150/jca.29294.CrossRefPubMedPubMedCentral

26.

Zhang RX, Ma WJ, Gu YT, Zhang TQ, Huang ZM, Lu ZH, et al. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis. World J Surg Oncol. 2017;15(1):138. https://doi.org/10.1186/s12957-017-1198-0.CrossRefPubMedPubMedCentral

27.

Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract. 2012;208(10):592–7. https://doi.org/10.1016/j.prp.2012.07.003.CrossRefPubMed

28.

Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R, et al. Colon carcinoma--classification into right and left sided cancer or according to colonic subsite?--analysis of 29,568 patients. Eur J Surg Oncol. 2011;37(2):134–9. https://doi.org/10.1016/j.ejso.2010.12.004.CrossRefPubMed

29.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal Cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062–72. https://doi.org/10.1158/1078-0432.CCR-17-2484.CrossRef

30.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3):dju427. https://doi.org/10.1093/jnci/dju427.

31.

Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, et al. Embryonic origin of primary Colon Cancer predicts pathologic response and survival in patients undergoing resection for Colon Cancer liver metastases. Ann Surg. 2018;267(3):514–20. https://doi.org/10.1097/SLA.0000000000002087.CrossRefPubMedPubMedCentral

32.

Arru M, Aldrighetti L, Castoldi R, Di Palo S, Orsenigo E, Stella M, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2008;32(1):93–103. https://doi.org/10.1007/s00268-007-9285-y.CrossRefPubMed

33.

Konopke R, Distler M, Ludwig S, Kersting S. Location of liver metastases reflects the site of the primary colorectal carcinoma. Scand J Gastroenterol. 2008;43(2):192–5. https://doi.org/10.1080/00365520701677755.CrossRefPubMed

34.

Ito K, Shimizu A, Tsukuda T, Sasaki K, Tanabe M, Matsunaga N, et al. Evaluation of intraportal venous flow distribution by unenhanced MR angiography using three-dimensional fast spin-echo with a selective tagging pulse: efficacy of subtraction of tag-on and tag-off images acquired during a single breath-hold. J Magn Reson Imaging. 2009;29(5):1224–9. https://doi.org/10.1002/jmri.21764.CrossRefPubMed

35.

Kadiyoran C, Cizmecioglu HA, Cure E, Yildirim MA, Yilmaz PD. Liver metastasis in colorectal cancer: evaluation of segmental distribution. Prz Gastroenterol. 2019;14(3):188–92. https://doi.org/10.5114/pg.2019.88168.CrossRefPubMedPubMedCentral

36.

Wigmore SJ, Madhavan K, Redhead DN, Currie EJ, Garden OJ. Distribution of colorectal liver metastases in patients referred for hepatic resection. Cancer. 2000;89(2):285–7. https://doi.org/10.1002/1097-0142(20000715)89:2<285::AID-CNCR12>3.0.CO;2-#.CrossRefPubMed

37.

Lau JWL, Chang HSY, Lee KY, Gwee YX, Lee WQ, Chong CS. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival? ANZ J Surg. 2018;88(11):E772–7. https://doi.org/10.1111/ans.14726.CrossRefPubMed

38.

Lau JW, Chang HS, Lee KY, Gwee YX, Lee WQ, Chong CS. Survival outcomes following primary tumor resection for patients with incurable metastatic colorectal carcinoma: experience from a single institution. J Dig Dis. 2018;19(9):550–60. https://doi.org/10.1111/1751-2980.12657.CrossRefPubMed

39.

Xu H, Xia Z, Jia X, Chen K, Li D, Dai Y, et al. Primary tumor resection is associated with improved survival in stage IV colorectal Cancer: an instrumental variable analysis. Sci Rep. 2015;5(1):16516. https://doi.org/10.1038/srep16516.CrossRefPubMedPubMedCentral

40.

Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4):797–807. https://doi.org/10.1007/s00268-009-0366-y.CrossRefPubMed

41.

Clancy C, Burke JP, Barry M, Kalady MF, Calvin CJ. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014;21(12):3900–8. https://doi.org/10.1245/s10434-014-3805-4.CrossRefPubMed

42.

Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11. https://doi.org/10.1158/0008-5472.CAN-03-2646.CrossRefPubMed

43.

Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98–101.PubMed

44.

van der Wal GE, Gouw AS, Kamps JA, Moorlag HE, Bulthuis ML, Molema G, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg. 2012;255(1):86–94. https://doi.org/10.1097/SLA.0b013e318238346a.CrossRefPubMed

45.

Anwar S, Peter MB, Dent J, Scott NA. Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review. Color Dis. 2012;14(8):920–30. https://doi.org/10.1111/j.1463-1318.2011.02817.x.CrossRef

46.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 318-321. https://doi.org/10.1097/00000658-199909000-00004.CrossRefPubMedPubMedCentral

47.

Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, et al. The tumor burden score: a new "metro-ticket" prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132–41. https://doi.org/10.1097/SLA.0000000000002064.CrossRefPubMed

48.

Margonis GA, Sasaki K, Gholami S, Kim Y, Andreatos N, Rezaee N, et al. Genetic and morphological evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018;105(9):1210–20. https://doi.org/10.1002/bjs.10838.CrossRefPubMedPubMedCentral

49.

Mao R, Zhao JJ, Bi XY, Zhang YF, Li ZY, Zhou JG, et al. Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: a retrospective cohort study. Int J Surg. 2018;53:371–7. https://doi.org/10.1016/j.ijsu.2017.12.001.CrossRefPubMed

50.

Oshi M, Margonis GA, Sawada Y, Andreatos N, He J, Kumamoto T, et al. Higher tumor burden neutralizes negative margin status in hepatectomy for colorectal Cancer liver metastasis. Ann Surg Oncol. 2019;26(2):593–603. https://doi.org/10.1245/s10434-018-6830-x.CrossRefPubMed

51.

Campos-da-Paz M, Dorea JG, Galdino AS, Lacava ZGM. de Fatima Menezes Almeida Santos M. Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal Cancer: update on biomarker for clinical and biotechnological approaches. Recent Pat Biotechnol. 2018;12(4):269–79. https://doi.org/10.2174/1872208312666180731104244.CrossRefPubMed

52.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27. https://doi.org/10.1200/JCO.2006.08.2644.CrossRefPubMed

53.

Lipska L, Visokai V, Levy M, Svobodova S, Kormunda S, Finek J. Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Res. 2007;27(4A):1901–5.PubMed

54.

Pakdel A, Malekzadeh M, Naghibalhossaini F. The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients. Cancer Biomark. 2016;16(2):245–52. https://doi.org/10.3233/CBM-150561.CrossRefPubMed

55.

Bhatnagar J, Tewari HB, Bhatnagar M, Austin GE. Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res. 1999;19(3B):2181–7.PubMed

56.

Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981;71(2):246–53. https://doi.org/10.1016/0002-9343(81)90125-X.CrossRefPubMed

57.

Yan C, Hu Y, Zhang B, Mu L, Huang K, Zhao H, et al. The CEA−/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells. Oncotarget. 2016;7(49):80700–15. https://doi.org/10.18632/oncotarget.13029.CrossRefPubMedPubMedCentral

58.

Kim CW, Shin US, Yu CS, Kim JC. Clinicopathologic characteristics, surgical treatment and outcomes for splenic flexure colon cancer. Cancer Res Treat. 2010;42(2):69–76. https://doi.org/10.4143/crt.2010.42.2.69.CrossRefPubMedPubMedCentral

59.

van Rongen I, Damhuis RA, van der Hoeven JA, Plaisier PW. Comparison of extended hemicolectomy versus transverse colectomy in patients with cancer of the transverse colon. Acta Chir Belg. 2013;113(2):107–11. https://doi.org/10.1080/00015458.2013.11680895.CrossRefPubMed

60.

Odermatt M, Siddiqi N, Johns R, Miskovic D, Khan O, Khan J, et al. Short- and long-term outcomes for patients with splenic flexure tumours treated by left versus extended right colectomy are comparable: a retrospective analysis. Surg Today. 2014;44(11):2045–51. https://doi.org/10.1007/s00595-013-0803-2.CrossRefPubMed

61.

Chong CS, Huh JW, Oh BY, Park YA, Cho YB, Yun SH, et al. Operative method for transverse Colon carcinoma: transverse colectomy versus extended colectomy. Dis Colon Rectum. 2016;59(7):630–9. https://doi.org/10.1097/DCR.0000000000000619.CrossRefPubMed

62.

Leijssen LGJ, Dinaux AM, Amri R, Kunitake H, Bordeianou LG, Berger DL. A transverse colectomy is as safe as an extended right or left colectomy for mid-transverse Colon Cancer. World J Surg. 2018;42(10):3381–9. https://doi.org/10.1007/s00268-018-4582-1.CrossRefPubMed

63.

Aldridge MC, Phillips RK, Hittinger R, Fry JS, Fielding LP. Influence of tumour site on presentation, management and subsequent outcome in large bowel cancer. Br J Surg. 1986;73(8):663–70. https://doi.org/10.1002/bjs.1800730829.CrossRefPubMed

64.

Sadler GP, Gupta R, Foster ME. Carcinoma of the splenic flexure--a case for extended right hemicolectomy? Postgrad Med J. 1992;68(800):487. https://doi.org/10.1136/pgmj.68.800.487.CrossRefPubMedPubMedCentral

65.

Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433–41. https://doi.org/10.1093/jnci/djk092.CrossRefPubMed

66.

Manceau G, Benoist S, Panis Y, Rault A, Mathonnet M, Goere D, et al. Elective surgery for tumours of the splenic flexure: a French inter-group (AFC, SFCD, FRENCH, GRECCAR) survey. Tech Coloproctol. 2020;24(2):191–8. https://doi.org/10.1007/s10151-019-02143-2.CrossRefPubMed

67.

Binda GA, Amato A, Alberton G, Bruzzone M, Secondo P, Lopez-Borao J, et al. Surgical treatment of a colon neoplasm of the splenic flexure: a multicentric study of short-term outcomes. Color Dis. 2020;22(2):146–53. https://doi.org/10.1111/codi.14832.CrossRef

68.

Hajibandeh S, Hajibandeh S, Hussain I, Zubairu A, Akbar F, Maw A. Comparison of extended right hemicolectomy, left hemicolectomy and segmental colectomy for splenic flexure colon cancer: a systematic review and meta-analysis. Color Dis. 2020;22(12):1885–907. https://doi.org/10.1111/codi.15292.CrossRef

69.

Morarasu S, Clancy C, Cronin CT, Matsuda T, Heneghan HM, Winter DC. Segmental versus extended colectomy for tumours of the transverse colon: a systematic review and meta-analysis. Color Dis. 2020;23(3):625–34. https://doi.org/10.1111/codi.15403.

70.

Bademci R, Bollo J, Martinez Sanchez C, Hernadez P, Targarona EM. Is segmental Colon resection an alternative treatment for splenic flexure Cancer? J Laparoendosc Adv Surg Tech A. 2019;29(5):621–6. https://doi.org/10.1089/lap.2019.0041.CrossRefPubMed

71.

Degiuli M, Reddavid R, Ricceri F, Di Candido F, Ortenzi M, Elmore U, et al. Segmental colonic resection is a safe and effective treatment option for Colon Cancer of the splenic flexure: a Nationwide retrospective study of the Italian Society of Surgical Oncology-colorectal Cancer network collaborative group. Dis Colon Rectum. 2020;63(10):1372–82. https://doi.org/10.1097/DCR.0000000000001743.CrossRefPubMed

72.

Rega D, Pace U, Scala D, Chiodini P, Granata V, Fares Bucci A, et al. Treatment of splenic flexure colon cancer: a comparison of three different surgical procedures: experience of a high volume cancer center. Sci Rep. 2019;9(1):10953. https://doi.org/10.1038/s41598-019-47548-z.CrossRefPubMedPubMedCentral

73.

Reddavid R, Esposito L, Evangelista A, Sofia S, Degiuli M. Non-anatomical colonic resections: splenic flexure and transverse colectomy. Central vascular ligation is crucial for survival. Minerva Chir. 2019;74(2):176–86. https://doi.org/10.23736/S0026-4733.18.07803-3.CrossRefPubMed

74.

Park IJ, Choi GS, Kang BM, Lim KH, Jun SH. Lymph node metastasis patterns in right-sided colon cancers: is segmental resection of these tumors oncologically safe? Ann Surg Oncol. 2009;16(6):1501–6. https://doi.org/10.1245/s10434-009-0368-x.CrossRefPubMed

75.

Pisani Ceretti A, Maroni N, Sacchi M, Bona S, Angiolini MR, Bianchi P, et al. Laparoscopic colonic resection for splenic flexure cancer: our experience. BMC Gastroenterol. 2015;15(1):76. https://doi.org/10.1186/s12876-015-0301-7.CrossRefPubMedPubMedCentral

76.

Nakagoe T, Sawai T, Tsuji T, Jibiki M, Ohbatake M, Nanashima A, et al. Surgical treatment and subsequent outcome of patients with carcinoma of the splenic flexure. Surg Today. 2001;31(3):204–9. https://doi.org/10.1007/s005950170169.CrossRefPubMed

77.

Phillips JW, Waugh JM, Dockerty MB. The surgical significance of regional lymphatic drainage of the hepatic flexure. Surg Gynecol Obstet. 1954;99(4):455–61.PubMed

78.

Martin Arevalo J, Moro-Valdezate D, Garcia-Botello SA, Pla-Marti V, Garces-Albir M, Perez Santiago L, et al. Propensity score analysis of postoperative and oncological outcomes after surgical treatment for splenic flexure colon cancer. Int J Color Dis. 2018;33(9):1201–13. https://doi.org/10.1007/s00384-018-3063-1.CrossRef

79.

Milone M, Manigrasso M, Elmore U, Maione F, Gennarelli N, Rondelli F, et al. Short- and long-term outcomes after transverse versus extended colectomy for transverse colon cancer. A systematic review and meta-analysis. Int J Color Dis. 2019;34(2):201–7. https://doi.org/10.1007/s00384-018-3186-4.CrossRef

80.

Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8. https://doi.org/10.1016/j.suronc.2018.05.012.CrossRefPubMed

81.

Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8. https://doi.org/10.1093/annonc/mdu580.CrossRefPubMed

82.

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus Bevacizumab as conversion therapy for patients with initially Unresectable metastatic colorectal Cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):e170278. https://doi.org/10.1001/jamaoncol.2017.0278.CrossRefPubMedPubMedCentral

83.

Kawai S, Takeshima N, Hayasaka Y, Notsu A, Yamazaki M, Kawabata T, et al. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer. 2021;21(1):116. https://doi.org/10.1186/s12885-021-07823-7.CrossRefPubMedPubMedCentral

84.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.CrossRefPubMed

85.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. https://doi.org/10.1093/annonc/mdx738.CrossRefPubMed

86.

Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, et al. Effect of KRAS and BRAF mutations on survival of metastatic colorectal Cancer after liver resection: a systematic review and meta-analysis. Clin Colorectal Cancer. 2017;16(3):e153–63. https://doi.org/10.1016/j.clcc.2017.01.004.CrossRefPubMed

87.

Datta J, Narayan RR, Goldman DA, Chatila WK, Gonen M, Strong J, et al. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004613.

88.

Ruzzenente A, Bagante F, Ratti F, Beal EW, Alexandrescu S, Merath K, et al. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. HPB (Oxford). 2019;21(9):1230–9. https://doi.org/10.1016/j.hpb.2019.01.014.CrossRef

89.

Margonis GA, Kim Y, Sasaki K, Samaha M, Buettner S, Amini N, et al. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. J Surg Oncol. 2016;114(3):361–7. https://doi.org/10.1002/jso.24319.CrossRefPubMed

90.

Yamashita S, Chun YS, Kopetz SE, Maru D, Conrad C, Aloia TA, et al. APC and PIK3CA mutational Cooperativity predicts pathologic response and survival in patients undergoing resection for colorectal liver metastases. Ann Surg. 2020;272(6):1080–5. https://doi.org/10.1097/SLA.0000000000002245.CrossRefPubMed

91.

Zaanan A, Taieb J. Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: who and how to treat? Bull Cancer. 2019;106(2):129–36. https://doi.org/10.1016/j.bulcan.2018.10.011.CrossRefPubMed

92.

Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, et al. Modified FOLFOXIRI with or without Cetuximab as conversion therapy in patients with RAS/BRAF wild-type Unresectable liver metastases colorectal Cancer: the FOCULM multicenter phase II trial. Oncologist. 2021;26(1):e90–8. https://doi.org/10.1634/theoncologist.2020-0563.CrossRefPubMed

93.

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. https://doi.org/10.1056/NEJMoa0805019.CrossRefPubMed

94.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65. https://doi.org/10.1056/NEJMoa0804385.CrossRefPubMed

95.

Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307–12. https://doi.org/10.1002/gcc.20854.CrossRefPubMed

96.

Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Color Dis. 2013;15(12):e711–8. https://doi.org/10.1111/codi.12427.CrossRef

97.

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497–507. https://doi.org/10.1016/S1470-2045(19)30862-9.CrossRefPubMed

98.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/S1470-2045(14)70330-4.CrossRef

99.

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK. A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7. https://doi.org/10.1200/JCO.2013.53.2473.CrossRefPubMed

100.

Lieu CH, Messersmith WA. Cetuximab or Bevacizumab with first-line chemotherapy in advanced KRAS wild-type colorectal Cancer: no difference, but not the same. JAMA. 2017;317(23):2376–8. https://doi.org/10.1001/jama.2017.6673.CrossRefPubMed

101.

Bennouna J, Hiret S, Bertaut A, Bouche O, Deplanque G, Borel C, Francois E, Conroy T, Ghiringhelli F, des Guetz G et al. continuation of Bevacizumab vs Cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal Cancer: the UNICANCER PRODIGE18 randomized clinical trial. JAMA Oncol 2019; 5(1):83–90, DOI: https://doi.org/10.1001/jamaoncol.2018.4465.

102.

Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, et al. Clinicopathological and molecular differences in colorectal cancer according to location. Int J Biol Markers. 2019;34(1):47–53. https://doi.org/10.1177/1724600818807164.CrossRefPubMed

103.

Natsume S, Yamaguchi T, Takao M, Iijima T, Wakaume R, Takahashi K, et al. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Jpn J Clin Oncol. 2018;48(7):609–18. https://doi.org/10.1093/jjco/hyy069.CrossRefPubMed

104.

Kalantzis I, Nonni A, Pavlakis K, Delicha EM, Miltiadou K, Kosmas C, et al. Clinicopathological differences and correlations between right and left colon cancer. World J Clin Cases. 2020;8(8):1424–43. https://doi.org/10.12998/wjcc.v8.i8.1424.CrossRefPubMedPubMedCentral

105.

Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol. 2020;11(10):761–808. https://doi.org/10.5306/wjco.v11.i10.761.CrossRefPubMedPubMedCentral

106.

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29. https://doi.org/10.1093/annonc/mdx175.CrossRefPubMedPubMedCentral

107.

Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6. https://doi.org/10.1038/nm.3967.CrossRefPubMedPubMedCentral

108.

Huang W, Li H, Shi X, Lin M, Liao C, Zhang S, et al. Characterization of genomic alterations in Chinese colorectal cancer patients. Jpn J Clin Oncol. 2021;51(1):120–9. https://doi.org/10.1093/jjco/hyaa182.CrossRefPubMed

109.

Chen TH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, et al. Effect of Primary Tumor Location on Postmetastasectomy Survival in Patients with Colorectal Cancer Liver Metastasis. J Gastrointest Surg. 2020;25(3):650–61. https://doi.org/10.1007/s11605-020-04855-5.

Title: Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis
Authors: Jiefeng Zhao
Jinfeng Zhu
Rui Sun
Chao Huang
Rongfa Yuan
Zhengming Zhu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08157-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience

MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors

Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer

Image-guided microwave ablation of hepatocellular carcinoma (≤5.0 cm): is MR guidance more effective than CT guidance?

LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer